491,466 Shares in Rezolute, Inc. (NASDAQ:RZLT) Purchased by Walleye Capital LLC

Walleye Capital LLC acquired a new stake in Rezolute, Inc. (NASDAQ:RZLT) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 491,466 shares of the company’s stock, valued at approximately $2,408,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in RZLT. Geode Capital Management LLC boosted its holdings in Rezolute by 39.0% during the third quarter. Geode Capital Management LLC now owns 491,601 shares of the company’s stock worth $2,385,000 after buying an additional 137,905 shares in the last quarter. MML Investors Services LLC acquired a new position in Rezolute in the 3rd quarter valued at about $57,000. JPMorgan Chase & Co. purchased a new position in shares of Rezolute during the third quarter valued at approximately $42,000. State Street Corp boosted its holdings in shares of Rezolute by 11.6% during the third quarter. State Street Corp now owns 125,472 shares of the company’s stock worth $609,000 after purchasing an additional 13,000 shares during the last quarter. Finally, Exome Asset Management LLC grew its position in shares of Rezolute by 24.7% in the third quarter. Exome Asset Management LLC now owns 352,056 shares of the company’s stock valued at $1,707,000 after purchasing an additional 69,656 shares during the period. Institutional investors and hedge funds own 82.97% of the company’s stock.

Rezolute Trading Up 4.2 %

Shares of RZLT stock opened at $2.75 on Friday. The company’s fifty day simple moving average is $3.47 and its 200-day simple moving average is $4.49. Rezolute, Inc. has a 52 week low of $2.22 and a 52 week high of $6.19. The company has a market cap of $166.47 million, a PE ratio of -2.25 and a beta of 0.97.

Rezolute (NASDAQ:RZLT) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.11. Equities research analysts expect that Rezolute, Inc. will post -0.93 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

RZLT has been the topic of several recent analyst reports. Craig Hallum upgraded Rezolute to a “strong-buy” rating in a research report on Tuesday, February 4th. Guggenheim reaffirmed a “buy” rating on shares of Rezolute in a research report on Monday, February 10th. HC Wainwright reaffirmed a “buy” rating and set a $14.00 price target on shares of Rezolute in a research note on Thursday, February 13th. Finally, JMP Securities upped their price objective on Rezolute from $8.00 to $9.00 and gave the stock a “market outperform” rating in a report on Thursday, February 13th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Rezolute presently has a consensus rating of “Buy” and a consensus price target of $26.43.

Insiders Place Their Bets

In other Rezolute news, CEO Nevan C. Elam purchased 12,302 shares of Rezolute stock in a transaction that occurred on Thursday, March 27th. The stock was purchased at an average price of $2.85 per share, with a total value of $35,060.70. Following the completion of the acquisition, the chief executive officer now owns 224,119 shares of the company’s stock, valued at approximately $638,739.15. This trade represents a 5.81 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Wladimir Hogenhuis purchased 10,000 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were bought at an average cost of $4.70 per share, with a total value of $47,000.00. Following the transaction, the director now directly owns 77,267 shares of the company’s stock, valued at approximately $363,154.90. This represents a 14.87 % increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 39,060 shares of company stock worth $130,694 in the last 90 days. 18.39% of the stock is owned by company insiders.

Rezolute Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.